Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis.
- Author:
Wenhao TANG
1
;
Yiqun GU
;
Jiansun TONG
;
Dingzhi MA
;
Xinghai WANG
;
Dong YUAN
;
Zhenwen CHEN
;
William J BREMNER
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Androgens; pharmacology; China; Gonadotropin-Releasing Hormone; biosynthesis; Humans; Hypothalamo-Hypophyseal System; metabolism; Male; Medroxyprogesterone Acetate; pharmacology; Prospective Studies; Sperm Count; Spermatogenesis; drug effects; Testosterone; analogs & derivatives; pharmacology
- From: National Journal of Andrology 2004;10(8):572-581
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe depot medroxyprogesterone acetate (DMPA) and testosterone undecanoate (TU) injected at 8-week intervals for the suppression of spermatogenesis in healthy Chinese men.
METHODSAfter screening, 30 healthy volunteers were enrolled and randomly assigned to 3 dosage-groups (n = 10/group): 1000 mg TU (Group A), 1000 mg TU plus 150 mg DMPA (Group B), 1000 mg TU plus 300 mg DMPA (Group C). All dosages were given as intramuscular injections at 8-week intervals. The study consisted of an 8-week control (baseline) period, a 24-week treatment period and a 24-week recovery period.
RESULTSConsistent azoospermia or severe oligozoospermia was achieved and maintained in all the volunteers during the treatment period, except 2 in the mere TU group who experienced a "rebound" in sperm concentrations. An 8-week regimen of TU plus DMPA at both tested combination dosages effectively suppressed spermatogenesis to azoospermia. All volunteers tolerated the injections; no serious adverse effects were reported.
CONCLUSIONThe lower combined dosage is recommended for further testing in an expanded clinical trial or contraceptive efficacy study.
